A Mayo-Careggi MPN Alliance study found that among 709 Mayo Clinic patients with PMF, 66% had a JAK2 mutation, 19% had a CALR mutation, and 5.4% had an MPL mutation. A further 10% of patients were triple-negative for these mutations.
Patients with a CALR type 1–like mutation had longer survival than those with JAK2 (hazard ratio [HR], 2.6; 95% CI, 1.9-3.5), CALR type 2–like (HR, 2.5; 95% CI 1.4-4.5), and MPL (HR, 1.8; 95% CI, 1.1-2.9) mutations and those with triple-negative mutational status (HR, 2.4; 95% CI, 1.6-3.6).
Learn more about a prognostic model for PMF that combines age and mutation status in the JAK2, CALR, and MPL genes.
Medscape © 2020 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Emmanuel C. Besa. Fast Five Quiz: Prognosis of Primary Myelofibrosis - Medscape - Jul 16, 2020.